专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2054602A Nucleic acid molecules encoding a poly(adp-ribose) polymerase 未知
公开(公告)号：AU2054602A
公开(公告)日：2002-03-26
申请号：AU2054602
申请日：2001-09-11
申请人： LUSCHER BERNHARD , AUSTEN MATTHIAS
发明人： LUSCHER BERNHARD , AUSTEN MATTHIAS
IPC分类号： A61K38/00 , C12N9/10 , C12N9/00

2. 发明申请

WO2010023181A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：用于药物组合物的三硝基嘧啶
公开(公告)号：WO2010023181A1
公开(公告)日：2010-03-04
申请号：PCT/EP2009/060876
申请日：2009-08-24
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , AUSTEN, Matthias , BLACK, Phillip , BLACKABY, Wesley , DANILEWICZ, John , LINNEY, Ian , SCHREITER, Kay , SCHNEIDER, Martin
发明人： AUSTEN, Matthias , BLACK, Phillip , BLACKABY, Wesley , DANILEWICZ, John , LINNEY, Ian , SCHREITER, Kay , SCHNEIDER, Martin
IPC分类号： C07D495/04 , A61K31/381 , A61P9/00
CPC分类号： C07D495/04
摘要： The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds according to formula (I). Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof wherein X is selected from CH or N.
摘要翻译：本发明涉及包含根据式（I）的噻吩并嘧啶化合物的新型药物组合物。此外，本发明涉及本发明的噻吩并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途或Mnk2b）和/或其变体，其中X选自CH或N.

3. 发明申请

WO2009059755A2 NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE 审中-公开
标题翻译：新型神经营养因子用于药物使用
公开(公告)号：WO2009059755A2
公开(公告)日：2009-05-14
申请号：PCT/EP2008009320
申请日：2008-11-05
申请人： DEVELOGEN AG , AUSTEN MATTHIAS , GEESE MARCUS , MUSSMANN RAINER , HARDER FRIEDRICH , SIEGMUND THOMAS
发明人： AUSTEN MATTHIAS , GEESE MARCUS , MUSSMANN RAINER , HARDER FRIEDRICH , SIEGMUND THOMAS
IPC分类号： A61K47/48 , A61K38/18 , A61P3/10 , A61P25/00 , C07K14/475
CPC分类号： C07K14/4756 , A61K9/0019 , A61K38/185 , A61K47/60
摘要： The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
摘要翻译：本发明涉及与多元醇缀合的neururin蛋白产物和包含neurturin偶联物作为活性成分的药物组合物，优选聚乙二醇化的neururin缀合物或其变体，具有增加的生物利用度。

4. 发明申请

WO2006117212A3 USE OF GSK-3 INHIBITORS FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS 审中-公开
公开(公告)号：WO2006117212A3
公开(公告)日：2006-11-09
申请号：PCT/EP2006/004170
申请日：2006-05-04
申请人： DEVELOGEN AKTIENGESELLSCHAFT , MUSSMANN, Rainer , AUSTEN, Matthias , KELTER, Arndt-Rene , HARDER, Friedrich , AICHER, Babette , LOMOW, Alexander
发明人： MUSSMANN, Rainer , AUSTEN, Matthias , KELTER, Arndt-Rene , HARDER, Friedrich , AICHER, Babette , LOMOW, Alexander
IPC分类号： A61P3/10
摘要： This invention relates to the use of Pax4 stimulating compounds, e.g. Glycogen synthase kinase-3 (GSK-3) inhibitors, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA. More particularly, this invention relates to the use of compounds selected from paullones, indirubines, substituted ureas, maleimide derivatives and pyrimidine thiones. Further, the present invention relates to a method of identifying and/or characterizing pancreatic beta-cell mitogens by using cells expressing a pancreatic gene or a gene whose function is controlled by a pancreatic gene, particularly the Pax4 gene, and which are transfected with a reporter gene.

5. 发明申请

WO2004044241A3 USE OF FISH LARVAE AS A SCREENING MODEL 审中-公开
标题翻译：作为筛选模型的鱼类LARVAE的使用
公开(公告)号：WO2004044241A3
公开(公告)日：2004-09-10
申请号：PCT/EP0312706
申请日：2003-11-13
申请人： DEVELOGEN AG , AUSTEN MATTHIAS
发明人： AUSTEN MATTHIAS
IPC分类号： G01N33/50 , G01N33/52 , C12Q1/68
CPC分类号： G01N33/52 , G01N33/5088 , G01N2333/4603
摘要： This present invention concerns the use of fish larvae, in particular zebrafish larvae or medaka larvae, as a model organism for investigating metabolism diseases, such as obesity and associated diseases, as well as for the development of corresponding prevention and/or treatment strategies. This present invention concerns, in particular, a procedure for the identification and/or characterization of genes and/or gene products or active substances which affect energy homeostasis as well as a pharmaceutical composition comprising genes, gene products or active substances identified by using the procedure in accordance with this present invention for the prevention and/or treatment of diseases, in particular metabolism diseases, such as obesity, and other diseases concerning the regulation of body weight as well as associated diseases, such as eating disorders, cachexia, diabetes mellitus, high blood pressure, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstone disorders, cancer, such as, for example, cancer of the genital organs, and sleep apnea. Furthermore, this present invention concerns a procedure for determining the fat content of fish larvae, in particular of zebrafish larvae or medaka larvae.
摘要翻译：本发明涉及鱼类幼虫，特别是斑马鱼幼虫或楝树幼虫作为模型生物体用于研究代谢疾病如肥胖症和相关疾病以及发展相应的预防和/或治疗策略的用途。本发明特别涉及用于鉴定和/或表征影响能量稳态的基因和/或基因产物或活性物质的方法，以及包含通过使用该程序鉴定的基因，基因产物或活性物质的药物组合物根据本发明，用于预防和/或治疗疾病，特别是代谢疾病，例如肥胖症和其它与体重调节有关的疾病以及相关疾病，如进食障碍，恶病质，糖尿病，高血压，冠心病，高胆固醇血症，血脂异常，骨关节炎，胆结石病，癌症，例如生殖器官的癌症和睡眠呼吸暂停。此外，本发明涉及用于测定鱼幼虫，特别是斑马鱼幼虫或稚贝幼虫的脂肪含量的方法。

6. 发明申请

WO2003099318A3 PANCREAS-SPECIFIC PROTEINS 审中-公开
公开(公告)号：WO2003099318A3
公开(公告)日：2003-12-04
申请号：PCT/EP2003/005700
申请日：2003-05-30
申请人： DEVELOGEN AKTIENGESELLSCHAFT FÜR ENTWICKLUNGSBIOLOGISCHE FORSCHUNG , DOHRMANN, Cord , AUSTEN, Matthias
发明人： DOHRMANN, Cord , AUSTEN, Matthias
IPC分类号： A61K38/17
摘要： The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the treatment, alleviation and/or prevention of pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), and related disorders, and other diseases and disorders.

7. 发明申请

WO2011104337A1 HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：用于药物组合物的含有环烷基的三烯丙基嘧啶
公开(公告)号：WO2011104337A1
公开(公告)日：2011-09-01
申请号：PCT/EP2011/052810
申请日：2011-02-25
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , LEHMANN-LINTZ, Thorsten , KLEY, Joerg , REDEMANN, Norbert , SAUER, Achim , THOMAS, Leo , WIEDENMAYER, Dieter , AUSTEN, Matthias , DANILEWICZ, John , SCHNEIDER, Martin , SCHREITER, Kay , BLACK, Phillip , BLACKABY, Wesley , LINNEY, Ian
发明人： LEHMANN-LINTZ, Thorsten , KLEY, Joerg , REDEMANN, Norbert , SAUER, Achim , THOMAS, Leo , WIEDENMAYER, Dieter , AUSTEN, Matthias , DANILEWICZ, John , SCHNEIDER, Martin , SCHREITER, Kay , BLACK, Phillip , BLACKABY, Wesley , LINNEY, Ian
IPC分类号： C07D495/04 , C07D519/00 , A61K31/519 , A61K31/5355 , A61K31/55 , A61P3/00 , A61P3/06 , A61P3/10 , A61P13/12 , A61P25/28 , A61P29/00 , A61P35/00
CPC分类号： C07D495/04 , C07D519/00
摘要： The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
摘要翻译：本发明涉及包含噻吩并嘧啶化合物的新型药物组合物。此外，本发明涉及本发明的噻吩并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）的激酶活性的疾病的用途或Mnk2b）和/或其变体。

8. 发明申请

WO2009065596A3 USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：使用MNK抑制剂治疗阿尔茨海默病
公开(公告)号：WO2009065596A3
公开(公告)日：2009-08-20
申请号：PCT/EP2008009880
申请日：2008-11-21
申请人： DEVELOGEN AG , AUSTEN MATTHIAS , GEESE MARCUS , SCHNEIDER MARTIN
发明人： AUSTEN MATTHIAS , GEESE MARCUS , SCHNEIDER MARTIN
IPC分类号： A61K31/519 , A61P25/28 , G01N33/15
CPC分类号： A61K31/519
摘要： The present invention relates to the use of modulators of the kinase activity of Mnk1 and/or Mnk2 the diagnosis, alleviation, treatment and/or prevention of a tauopathy. Particularly, the present invention relates to the use of a modulator of Mnk1 and/or Mnk2 kinase for the diagnosis, alleviation, treatment and/or prevention of Alzheimer's disease. Preferably, the compounds are condensed pyrimidines.
摘要翻译：本发明涉及Mnk1和/或Mnk2的激酶活性的调节剂在tau蛋白病的诊断，缓解，治疗和/或预防中的应用。特别地，本发明涉及Mnk1和/或Mnk2激酶的调节剂用于诊断，缓解，治疗和/或预防阿尔茨海默氏病的用途。优选地，化合物是稠合嘧啶。

9. 发明申请

WO2009065596A2 USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：使用MNK抑制剂治疗阿尔茨海默病
公开(公告)号：WO2009065596A2
公开(公告)日：2009-05-28
申请号：PCT/EP2008/009880
申请日：2008-11-21
申请人： DEVELOGEN AKTIENGESELLSCHAFT , AUSTEN, Matthias , GEESE, Marcus , SCHNEIDER, Martin
发明人： AUSTEN, Matthias , GEESE, Marcus , SCHNEIDER, Martin
IPC分类号： A61K31/519 , A61P25/28 , G01N33/15
CPC分类号： A61K31/519
摘要： The present invention relates to the use of modulators of the kinase activity of Mnk1 and/or Mnk2 the diagnosis, alleviation, treatment and/or prevention of a tauopathy. Particularly, the present invention relates to the use of a modulator of Mnk1 and/or Mnk2 kinase for the diagnosis, alleviation, treatment and/or prevention of Alzheimer's disease.
摘要翻译：本发明涉及Mnk1和/或Mnk2的激酶活性的调节剂在tau蛋白病的诊断，缓解，治疗和/或预防中的应用。特别地，本发明涉及Mnk1和/或Mnk2激酶的调节剂用于诊断，缓解，治疗和/或预防阿尔茨海默氏病的用途。

10. 发明申请

WO2006117212A2 USE OF GSK-3 INHIBITORS FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS 审中-公开
标题翻译：使用GSK-3抑制剂预防和治疗胰腺自身免疫疾病
公开(公告)号：WO2006117212A2
公开(公告)日：2006-11-09
申请号：PCT/EP2006004170
申请日：2006-05-04
申请人： DEVELOGEN AG , MUSSMANN RAINER , AUSTEN MATTHIAS , KELTER ARNDT-RENE , HARDER FRIEDRICH , AICHER BABETTE , LOMOW ALEXANDER
发明人： MUSSMANN RAINER , AUSTEN MATTHIAS , KELTER ARNDT-RENE , HARDER FRIEDRICH , AICHER BABETTE , LOMOW ALEXANDER
IPC分类号： A61P3/10
CPC分类号： A61K45/06 , A61K31/4015 , A61K31/404 , A61K31/55 , A61K2300/00
摘要： This invention relates to the use of Pax4 stimulating compounds, e.g. Glycogen synthase kinase-3 (GSK-3) inhibitors, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA. More particularly, this invention relates to the use of compounds selected from paullones, indirubines, substituted ureas, maleimide derivatives and pyrimidine thiones. Further, the present invention relates to a method of identifying and/or characterizing pancreatic beta-cell mitogens by using cells expressing a pancreatic gene or a gene whose function is controlled by a pancreatic gene, particularly the Pax4 gene, and which are transfected with a reporter gene.
摘要翻译：本发明涉及使用Pax4刺激化合物，例如，糖原合成酶激酶-3（GSK-3）抑制剂，特别是与免疫调节剂组合，用于预防和/或治疗胰腺自身免疫性疾病，例如， I型糖尿病或LADA。更具体地说，本发明涉及选自paullones，indirubines，取代的脲，马来酰亚胺衍生物和嘧啶硫酮的化合物的用途。此外，本发明涉及通过使用表达胰腺基因的细胞或其功能由胰腺基因特别是Pax4基因控制的基因来鉴定和/或表征胰腺β-细胞有丝分裂原的方法，并且用记者基因。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式